Powered by HumanexaHumanexa Review

Editorial intelligence for pharma strategy

AnalysisResearchOpinionCalendarNewsletterAbout
Pharma StrategyDrug DevelopmentCompetitive IntelligenceAI & HealthcareBiotech BusinessIndustry Analysis

Humanexa Review

Independent editorial analysis on pharma strategy, drug development, and market structure in life sciences.

Powered by Humanexa

AboutStudioNewsletterCalendar
Explore Humanexa Intelligence Platform

Category

Drug Development

Clinical design, translational science, and program execution.

Drug Development·Jun 26, 2026·1 min read

Adaptive Trials Are Becoming the Default, Not the Exception

FDA guidance and sponsor experience data suggest adaptive designs will dominate oncology and rare disease programs.

Humanexa Research

Newsletter

Weekly editorial intelligence

Curated analysis on pharma strategy, development, and competitive dynamics. No noise — just the signals that matter.

Contact review@humanexa.io for editorial inquiries.